Scarica l'app Stockscreener
203.55
0.16%
-0.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$203.87
Aprire:
$204.37
Volume 24 ore:
4.12M
Relative Volume:
0.93
Capitalizzazione di mercato:
$361.45B
Reddito:
$55.53B
Utile/perdita netta:
$5.12B
Rapporto P/E:
55.77
EPS:
3.65
Flusso di cassa netto:
$17.78B
1 W Prestazione:
+8.36%
1M Prestazione:
+3.35%
6M Prestazione:
+25.87%
1 anno Prestazione:
+42.87%
Intervallo 1D:
$202.32
$204.73
Intervallo di 1 settimana:
$187.52
$207.32
Portata 52W:
$135.85
$207.32
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Price Over Earnings Overview: AbbVie - Benzinga
AbbVie (NYSE:ABBV) Shares Up 0.1% Following Analyst Upgrade - MarketBeat
Expert Insights: The Promise of Genetic Medicine and AbbVie’s Role in Research - AbbVie
AbbVie and Gedeon Richter partner on neuropsychiatric conditions - The Pharma Letter
AbbVie raises profit forecast as CEO cites business "momentum" - MSN
AbbVie Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
AbbVie Inc. (NYSE:ABBV) Shares Bought by Principal Securities Inc. - MarketBeat
William Blair Estimates AbbVie's FY2024 Earnings (NYSE:ABBV) - MarketBeat
AbbVie and EvolveImmune Therapeutics sign oncology collaboration - Pharmaceutical Technology
Rx Rundown: AbbVie, Biogen, GSK and more - MM+M Online
AbbVie Stock Rises After Earnings Beat, Dividend Hike - MSN
AbbVie and EvolveImmune partner to develop advanced cancer therapies - World Pharmaceutical Frontiers
AbbVie’s Deal for Alzheimer’s Antibody Raises Curtain for Roche News on Wednesday - Barron's
UChicago gets $75M from AbbVie Foundation for new cancer center - The Business Journals
AbbVie (NYSE:ABBV) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
University of Chicago Medicine gets $75 million gift from AbbVie Foundation for new cancer center - CBS News
AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter
Evolveimmune snags another investor, inks $1.4B Abbvie deal - BioWorld Online
AbbVie (NYSE:ABBV) Trading 1.5% Higher After Better-Than-Expected Earnings - MarketBeat
AbbVie partners with EvolveImmune for cancer therapy - Investing.com
AbbVie's multibillion-dollar collaboration targets new cancer therapy candidate - Crain's Chicago Business
AbbVie price target raised to $200 from $195 at UBS - TipRanks
AbbVie (NYSE:ABBV) Hits New 12-Month High on Strong Earnings - MarketBeat
AbbVie (NYSE:ABBV) Price Target Raised to $231.00 - MarketBeat
AbbVie Foundation's $75M gift will put its name on new UChicago cancer hospital - Crain's Chicago Business
BMO increases AbbVie stock target, outperform on upbeat quarterly results - Investing.com
AbbVie Inc. (NYSE:ABBV) Q3 2024 Earnings Call Transcript - Insider Monkey
AbbVie Beats Q3 Estimates as Skyrizi, Rinvoq Pick Up Slack for Humira - BioSpace
AbbVie, EvolveImmune Therapeutics Set Cancer Biotherapeutics Collaboration - MarketWatch
Earnings call: AbbVie raises outlook on strong Q3 performance, Skyrizi and Rinvoq growth - Investing.com India
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-To- License Agreement to Develop Next-Generation Cancer Biotherapeutics - Marketscreener.com
AbbVie Inc. (NYSE:ABBV) Shares Bought by JFS Wealth Advisors LLC - MarketBeat
AbbVie (NYSE:ABBV) Updates Q4 2024 Earnings Guidance - MarketBeat
5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs - The Motley Fool
AbbVie Inc (ABBV) Q3 2024 Earnings Call Highlights: Strong Growth in Ex-Humira Platform and ... - Yahoo Finance
AbbVie reports 12% decline in Q3 2024 net income to $1.56bn - World Pharmaceutical Frontiers
AbbVie Reports Solid Q3 2024 Financial Performance - TipRanks
AbbVie: 3 Positives From The Earnings Report (NYSE:ABBV) - Seeking Alpha
AbbVie Inc. (NYSE:ABBV) Short Interest Up 8.9% in October - MarketBeat
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat - MSN
Super Micro, Alphabet, AMD, Lilly, Reddit, AbbVie, Qorvo, Garmin, and More Movers - Barron's
AbbVie Earnings: Maintaining Fair Value Estimate as Firm Rapidly Pushes Through Humira Headwind - Morningstar
AbbVie Stock Jumps After Upbeat Q3 Earnings, Revised Guidance: Retail Sentiment Hits One-Year High - Barchart
Reasons behind AbbVie Q3 revenue beat? (ABBV:NYSE) - Seeking Alpha
AbbVie stock soars to all-time high of $199.96 amid robust growth By Investing.com - Investing.com South Africa
Committee Stocks on the Move: Shake Shack, Chipotle, Wingstop, Visa and AbbVie - CNBC
AbbVie (ABBV) Q3 2024 Earnings Call Transcript - Nasdaq
AbbVie stock soars to all-time high of $199.96 amid robust growth - Investing.com Canada
AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View - Yahoo Finance
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.17%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):